Faculty Collaboration Database

Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients. Pediatr Nephrol 2000 Sep;14(10-11):908-11

Date

09/07/2000

Pubmed ID

10975297

DOI

10.1007/s004670000326

Scopus ID

2-s2.0-0033869462 (requires institutional sign-in at Scopus site)   18 Citations

Abstract

Recombinant human erythropoietin (rHuEPO) is an effective treatment for the anemia of chronic renal failure. However, adequate availability of iron is necessary for an optimal response. We prospectively evaluated the effect of an intravenous iron protocol in a pediatric hemodialysis unit. Patients with either a serum ferritin less than 150 ng/ml or transferrin saturation (TSAT) less than 20% received intravenous iron dextran during ten consecutive dialysis sessions. The administration of rHuEPO was adjusted using a protocol designed to maintain patient hematocrit between 33% and 36%. Thirteen courses of intravenous iron were evaluated. Patients received 4 mg/kg of iron dextran (maximum of 100 mg) during each of ten consecutive dialysis sessions. In 12 cases there was a decrease in rHuEPO use 2 months after completing the course of intravenous iron. The mean rHuEPO dose decreased from 3,784 units to 2,115 units (P<0.005). Based on the criteria of response to intravenous iron, a percentage iron saturation of less than 20% had a high specificity for detecting iron deficiency. All patients who received a course of intravenous iron had a TSAT less than 20%. The measurement of serum ferritin was less useful in our patients.

Author List

Greenbaum LA, Pan CG, Caley C, Nelson T, Sheth KJ

Author

Cynthia G. Pan MD Adjunct Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adolescent
Anemia
Child
Dose-Response Relationship, Drug
Erythropoietin
Ferritins
Humans
Injections, Intravenous
Iron-Dextran Complex
Kidney Failure, Chronic
Pilot Projects
Prospective Studies
Recombinant Proteins
Renal Dialysis